Polymyxin Combinations: Pharmacokinetics and Pharmacodynamics for Rationale Use (original) (raw)

Colistin: The Revival of Polymyxins for the Management of Multidrug-Resistant Gram-Negative Bacterial Infections

Clinical Infectious Diseases, 2005

International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti‐infecti...

ilias Karaiskos

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

View PDFchevron_right

Pharmacokinetics/pharmacodynamics of colistin and polymyxin B: are we there yet?

Phillip Bergen

Carolina Digital Repository (University of North Carolina at Chapel Hill), 2016

View PDFchevron_right

Polymyxin Monotherapy vs. Combination Therapy for the Treatment of Multidrug-resistant Infections: A Systematic Review and Meta-analysis

samir samal

Indian Journal of Critical Care Medicine : Peer-reviewed, Official Publication of Indian Society of Critical Care Medicine, 2021

View PDFchevron_right

Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus

David Paterson

The Lancet Infectious Diseases, 2015

View PDFchevron_right

Optimizing Polymyxin Combinations Against Resistant Gram-Negative Bacteria

Cornelia Landersdorfer

Infectious diseases and therapy, 2015

View PDFchevron_right

Pharmacokinetics and pharmacodynamics of ‘old’ polymyxins: what is new?

Phillip Bergen

Diagnostic Microbiology and Infectious Disease, 2012

View PDFchevron_right

Polymyxins combined with other antibiotics for the treatment of multi-resistant Gram negative bacteria: review of the literature

Maria Helena Rigatto

Principles and Practice of Clinical Research

View PDFchevron_right

The Clinical Efficacy of Polymyxin Monotherapy versus Non-validated Polymyxin Combination Therapy versus Validated Polymyxin Combination Therapy in Extensively Drug-Resistant Gram-Negative Bacilli Infections

Andrea Kwa

Antimicrobial agents and chemotherapy, 2016

View PDFchevron_right

Antimicrobial Susceptibility Testing for Polymyxins: Challenges, Issues, and Recommendations

Abdollah Ardebili

Journal of Clinical Microbiology, 2018

View PDFchevron_right

Polymyxins: a review of the current status including recent developments

Andrea Kwa

Annals of the Academy of Medicine, Singapore, 2008

View PDFchevron_right

Polymyxin B and colistimethate are comparable as to efficacy and renal toxicity

Gladys Prado

Diagnostic Microbiology and Infectious Disease, 2009

View PDFchevron_right

Contemporary Assessment of Antimicrobial Susceptibility Testing Methods for Polymyxin B and Colistin: Review of Available Interpretative Criteria and Quality Control Guidelines

ana gales

2001

View PDFchevron_right

An alternative strategy for combination therapy: Interactions between polymyxin B and non-antibiotics

Wendy Kloezen

International Journal of Antimicrobial Agents, 2018

View PDFchevron_right

Global survey of polymyxin use: A call for international guidelines

Heiman Wertheim

Journal of Global Antimicrobial Resistance, 2013

View PDFchevron_right

Polymyxins: Antimicrobial susceptibility concerns and therapeutic options

balaji veeraraghavan

Indian Journal of Medical Microbiology, 2011

View PDFchevron_right

Polymyxins, the last-resort antibiotics: Mode of action, resistance emergence, and potential solutions

Sambit Kumar Dwibedy

Journal of Biosciences, 2021

View PDFchevron_right

Effectiveness and safety of polymyxin B for the treatment of infections caused by extensively drug-resistant Gram-negative bacteria in Thailand

Narisorn Lorchirachoonkul

Infection and Drug Resistance, 2018

View PDFchevron_right

Polymyxins: To Combine or Not to Combine?

Robert Bonomo

Antibiotics, 2019

View PDFchevron_right

Polymyxins: Wisdom Does Not Always Come With Age

John Rotschafer

Clinical Infectious Diseases, 2013

View PDFchevron_right

Can colistin susceptibility results determined in multidrug resistant Gram-negative bacteria be used for polymyxin B?

Rıza Adaleti

Postępy Higieny i Medycyny Doświadczalnej

View PDFchevron_right

Polymyxin: Alternative Mechanisms of Action and Resistance

Milan Kolar

Cold Spring Harbor Perspectives in Medicine, 2016

View PDFchevron_right

Novel Polymyxin Combination With Antineoplastic Mitotane Improved the Bacterial Killing Against Polymyxin-Resistant Multidrug-Resistant Gram-Negative Pathogens

Phillip Bergen

Frontiers in microbiology, 2018

View PDFchevron_right

Development of new polymyxin derivatives for multi-drug resistant Gram-negative infections

Michael Dawson

The Journal of antibiotics, 2017

View PDFchevron_right

Therapeutic Specification of the Last Resort Polymyxins: An Intelligent Approach

jahidul hasan

International Journal of Infection

View PDFchevron_right

Polymyxin monotherapy or in combination against carbapenem-resistant bacteria: systematic review and meta-analysis

Habip Gedik

The Journal of antimicrobial chemotherapy, 2016

View PDFchevron_right

An Update on the arsenal for multidrug-resistant Acinetobacter infections: Polymyxin antibiotics

Rupali Jain

International Journal of Infectious Diseases, 2015

View PDFchevron_right

Polymyxin Combinations: Pharmacokinetics and Pharmacodynamics for Rationale Use (original) (raw)

Related papers